Introduction
In the last two decades, management of renal calculi has changed significantly. Extracorporeal shock-wave lithotripsy (ESWL) has revolutionized the treatment of kidney stones [1] . Open surgical removal of renal calculi has largely been replaced by minimally invasive techniques. Traditionally, residual fragments after open surgery might be considered as treatment failure. However, the presence of stone fragments after minimally invasive surgery, in particular ESWL, is common, as the stone clearance is not immediate.
Definition
Residual fragments are defined as all fragments remaining in the kidney after the last session of ESWL. Those fragments larger than 5 mm are generally considered to indicate treatment failure for ESWL. Small residual fragments are likely to pass spontaneously and remain asymptomatic. A new term, clinically insignificant residual fragments (CIRF), is used to describe such posttreatment stones. CIRF usually are ESWL residual fragments that are smaller than 4 mm (or sometimes 5 mm), asymptomatic, non-obstructive, non-infectious, and associated with sterile urine [2, 3] . Despite the widespread use of the term, CIRF remain a controversial problem after ESWL. The significance and fate of CIRF after treatment remains unclear. This article reviews the current literature with regards to the management of CIRF.
Outcome of clinically insignificant residual fragments
Residual fragments are important in that they may act as nidi for recurrent stone growth. They might also become symptomatic with pain and infection when obstruction occurs. They might present as a source of infection.
Zanetti et al. [4] reviewed the long-term outcome and therapeutic implications of a selected group of asymptomatic patients with fragments and dust 3 months after extracorporeal treatment. A total of 129 patients with dust and residual fragments (less than 4 mm) at 3 months were re-examined at 12 months, and 95 were also evaluated at 24 months. Follow-up examinations consisted of radiographic studies, renal ultrasonography and urine culture. Dust and residual fragments were sought, and patients were defined as free or as having persistent lithiasis or stone re-growth. At the 12-month follow up, 60 patients (46.5%) were stone-free and 56 (43.5%) still had dust or residual fragments. The localization of the stones or fragments at 3 months and their sizes did not have a significant influence on the stone-free rate but re-growth was greater in patients with stones larger than 10 mm (11 of 40 patients, 27.5%, versus 2 of 89, 2.2%; P ¼ 0.001). The probability of eliminating residual lithiasis at 12 months was significantly greater in patients with dust than in those with residual fragments (42 of 79 patients, 58%, versus 18 of 50, 36%; P ¼ 0.026). Re-growth of residual lithiasis was observed in 13 patients (10%). They concluded that patients with fragments do not require systematic re-treatment in the short-term but they may be followed long-term and re-treated if symptoms persist or stones recur.
Streem et al. [5] determined the natural history and clinical significance of small, asymptomatic, non-infection related stone fragments after ESWL. They prospectively followed up 160 patients with 4 mm or less asymptomatic calcium oxalate/phosphate stone fragments after ESWL for a mean of 23 months. Stone-free status or a decreased, stable or increased amount of residual stone occurred in 38 (23.8%), 26 (16.3%), 67 (41.9%) and 29 (18.1%) of the 160 patients, respectively. At 5 years after ESWL the probability of a stone-free, stone-free or decreased status, or stone-free decreased or stable status was 0.36, 0.53, and 0.80, respectively. A total of 91 patients (56.9%) remained asymptomatic while 69 (43.1%) had a symptomatic episode or required intervention 1.6-85.4 months (mean 26) after ESWL (probability estimated at 0.71 at 5 years). They concluded that while patients with small non-infection could be related stone fragments after ESWL followed expectantly, a significant number would require intervention or have symptomatic episodes within 2 years. In their opinion, the application of the term CIRF after ESWL may not be appropriate.
Candau et al. [6] retrospectively reviewed the natural history and clinical significance of 97 non-infected and isolated residual fragments (4 mm or less) observed 3 months after the last ESWL session on renal tomography. These residual fragments were mostly localized in the inferior calyx (62%). Median follow up was 40.6 months (range, 7-96 months). Stone-free status, or a decreased, stable, or increased amount of residual stone occurred in 27 (33%), 1 (1%), 24 (29%), and 31 (37%) of the 83 patients, respectively. During this study, 18 patients (22%) were proposed for a complementary treatment related to a size increase of the residual fragments (13 ESWL, one retrograde endoscopy, three percutaneous nephrolithotomy, and one polar inferior nephrectomy). In view of the secondary procedures required, the group felt that the term clinically insignificant should not be employed to describe residual fragment after ESWL. Residual fragments should not be considered as success of ESWL and cannot be incorporated in the percentage of stone-free patients. Efforts should be performed to obtain true stone-free status after ESWL.
In a separate study by Khaitan, 81 patients were followed up for 6-60 months (mean 15) after ESWL to determine the fate of the CIRF. Of the 81 patients, six were lost to follow up, leaving 75 patients. During follow up, fragments passed spontaneously in 18 patients, remained stable in 13 patients, and became clinically significant in 44 patients who developed one or more complications. For the latter patients, repeat ESWL was done in 16, percutaneous nephrolithotomy in three, and ureteroscopic stone removal was done in four patients. The remaining 21 patients were treated conservatively with analgesics. It was found that 53% of the CIRF located in the pelvis passed spontaneously, and most of the CIRF in the caliceal location became clinically significant. Also, as the stone burden and number of stone fragments increased, the risk of CIRF becoming clinically significant increased. They found that the outcome was the same whether a metabolic abnormality was present or not, provided the patient received an appropriate treatment. The clearance rate was highest in the first 6 months. Finally, as the duration of follow up increased, the rate of complications increased. They concluded that patients with residual stones after ESWL required close follow up and timely adjuvant therapy. As the number and size of residual fragments increased, the risk of complications increased. A pelvic location was a favorable factor for spontaneous passage. Metabolic defects, if treated adequately, did not increase the re-growth rate. Although the complete clearance rate of CIRFs with repeated ESWL was lower than for the operative interventions, most patients improved with this modality. They believed that CIRF are a myth and the concept needs to be re-defined.
Buchholz et al. [7] studied the fate of residual stone fragments <5 mm after ESWL over a sufficiently long period to determine how many are spontaneously cleared and after what time interval. The study also aimed to clarify their role in clinical outcome and stone recurrence and re-growth. The clinical and radiologic data of 266 patients were analyzed with a mean follow up of 387 days. After ESWL, 55 patients (21%) had residual fragments <5 mm in diameter. No significant differences between the stone-free patients and those with residual fragments with regard to age, sex, relevant medical history, or ESWL treatment were observed. After a mean follow up of 2.5 years, 12.7% of the residual fragments had not passed spontaneously, but all of them were clinically silent and located exclusively in the lower calices and the proximal ureter. Only 2% of the patients with residual fragments showed stone re-growth, and no stone recurrences were observed within the follow-up period. They concluded more invasive attempts to clear all minor fragments did not seem warranted.
In a separate study, Demirkesen et al. [8] reviewed their experience with ESWL for stones in abnormal urinary tracts and compared the results with those in normal urinary tracts. The study group was composed of 2566 renal units treated on the Siemens Lithostar lithotripter whose treatment and follow up at 10-12 weeks was completed. Sixty-eight renal units (2.7%) belonged to 52 patients who had congenital upper urinary tract abnormalities. It was found that the age, stone load, stone location, and the type of abnormality did not have a statistically significant impact on the outcome of ESWL for abnormal renal unit. The average stone load was 2.1 AE 2.8 cm 2 in the abnormal and 1.4 AE 1.3 cm 2 in the normal renal unit. Thus, the stone load was significantly higher in the abnormal renal unit (P < 0.05). In the abnormal group, 56% of the renal unit became stonefree, 37% had non-obstructive and non-infectious CIRF 4 mm, and SWL failed in 7%. In the normal group, 78% of the renal units became stone-free, 18.5% had CIRF, and SWL failed in 4%. The difference in the success rates was not significant in the groups if success was defined as stone-free and CIRF together (P > 0.05). However, there was a significant difference when stone-free, CIRF, and failure rates were evaluated separately (P < 0.05). Recurrence, re-growth, and re-treatment rates in abnormal renal unit were 50, 37, and 34%, respectively. They concluded that although the fragmentation rates were similar, clearance of the fragments was hampered in abnormal urinary tracts. Thus, especially for large stones, other endourologic treatment options should be considered. High recurrence and re-growth rates warrant careful monitoring and consideration for medical treatment during follow up.
Rassweiler et al. [3] did a literature review of studies consisting of more than 14 000 patients and compared these data with long-term results of two major stone centers in Germany. The results have been compared concerning the anatomical kidney situation, stone size, stone localization, and observation time. According to the importance of residual fragments following ESWL, CIRF and clinically significant residual fragments have to be distinguished separately. Twenty-four months following ESWL, stone passage occurs as a continuous process. Newer ESWL technology has increased the percentage of CIRF. In the review of various studies, they noted that 25 and 55% patients with CIRF would be stone-free or remain clinically insignificant respectively during follow up. Only 20% of CIRF, however, would become clinically significant. If there are no clinical symptoms, any endoscopic procedure should be considered as over-treatment. Only 4-25% patients required a secondary intervention which mostly consisted of a repeat ESWL.
In children, the fate of CIRF is not well known. The definition is extrapolated from adult experience, which may not hold true for pediatric cases. In a study by Afshar [9 ] , they evaluated the outcome of small residual stone fragments following ESWL in children. The medical records of 39 boys and 44 girls (88 renal units) with urolithiasis who underwent ESWL were reviewed. Median patient age was 7 years. Average stone burden was 14 mm. Mean follow up was 46 months. After the first ESWL 40 of the 88 (46%) renal units became stone-free and 18 (20%) had residual fragments 5 mm or less. The remaining 30 (34%) units required further treatment using ESWL or ancillary surgical procedures that rendered 12 of them stone-free and eight with residual fragments. The 26 renal units with residual fragments constitute the study patients. Adverse outcomes such as growth of residual fragments, symptomatic episodes, or calculi recurrence in stone-free cases were recorded. Of the 26 renal units with residual fragments 5 mm or less, 18 (69%) had an adverse clinical outcome (symptoms or residual fragments growth) and 8 (31%) patients were asymptomatic and had no stone growth. Patients with residual fragments had a significant increase in adverse clinical outcome compared to stone-free patients, with an odds ratio of 3.9. The presence of metabolic disorders was associated with residual fragments growth (odds ratio 11.4). Their experience showed that small residual fragments after ESWL are clinically significant in children and increase the chance of adverse clinical outcome. These patients require close follow up, particularly those with identifiable predisposing disorders.
Repeat extracorporeal shock-wave lithotripsy of clinically insignificant residual fragments
In order to promote residual stone clearance, some investigators have proposed re-treatment of residual fragments using ESWL with or without additional measures [10] [11] [12] .
The series from Parr et al. [10] adopted a policy of further ESWL for patients with CIRF in an attempt to promote complete clearance. A series of 22 patients with a mean initial stone burden of 16 mm (range, 7-48) developed CIRF after a median of two ESWL treatment sessions (range, 1-9). CIRF were in the lower calices (n ¼ 20), middle calices (n ¼ 1), and upper calices (n ¼ 1). These calices were normal (n ¼ 6), slightly dilated (n ¼ 9), moderately dilated (n ¼ 2), or grossly dilated (n ¼ 5). After 6-14 months, patients underwent a further session of ESWL. One month later, three patients with normal calices showed a considerable reduction in CIRF, but all other patients showed no change. When CIRF form in normal calices, a further session of ESWL may promote clearance. However, when calices containing CIRF are significantly dilated, further ESWL is of no value.
In a study by Moon and Kim [11] , the stone-free rate of 248 cases of clinically insignificant residual fragments was 32.7% by 1 month, 73.0% by 3 months, and 92.7% by 6 months of follow up. The stone-free rate decreased but not remarkably in accordance with the increment of the caliceal dilatation (92.9, 94.9, 85.7, and 83.3% for no, mild, moderate, and severe dilatation, respectively) by 6 months of follow up. The clearance of the CIRF was not influenced by their location, the pelviocaliceal angle, the infundibular length, or the number of the lower calices. Of 16 patients who had residual stone fragments at 6 months and underwent an additional session of ESWL, 12 became stone-free by another 6 months of follow up. Therefore, it is desirable to wait for clearance of CIRF for at least 6 months before offering further treatment, regardless of their location and anatomic variation of the calices containing CIRF. Repeated ESWL, even for stone fragments of 3-4 mm in diameter found in the initial 1 month after the last session of SWL, might promote clearance of the CIRF, and additional ESWL for persistent CIRF could be an appropriate adjunctive measure.
Pace et al. [12] compared the effectiveness of mechanical percussion and inversion with observation for eliminating lower caliceal fragments 3 months after shock-wave lithotripsy. At 3 months after shock-wave lithotripsy 69 patients with residual lower caliceal fragments of 4 mm or less were randomized to receive either mechanical percussion and inversion or observation for 1 month. The observation group then received crossover mechanical percussion and inversion if fragments persisted. Patients were treated with a mechanical chest percussor applied to the flank while inverted to greater than 608 after receiving 20 mg furosemide. The mechanical percussion and inversion group had a substantially higher stone-free rate than the observation group (40 versus 3%, respectively, P < 0.001). The mechanical percussion and inversion group also had a greater improvement in total stone area than controls (À63.3 versus þ2.7%, respectively, P < 0.001). No significant adverse effects were noted in the mechanical percussion and inversion group. The group believed that mechanical percussion and inversion is a safe and effective treatment option for residual lower which has the potential to enlarge with time and cause renal colic, obstruction or infection. Nearly 50% of patients become stone-free, and stone burden is decreased by 50% in the remainder.
Medical treatment
Medical therapy has been shown to be effective in preventing stone growth and recurrence [13] . Some investigators [14] [15] [16] have studied the result of metabolic therapy in the management of residual fragments.
In a study with a mean follow up of 12 months, Cicerello et al. [14] evaluated the hypothesis that alkaline citrate therapy improved residual stone-fragment clearance. Forty sterile-calcium-stone and 30 struvite-stone patients with residual fragments after ESWL (diameter less than 5 mm) were randomly assigned to a citrate therapy (6-8 g per day) or control (hygienic measures only) group. Infection-stone patients also received adequate antibiotic therapy throughout the study. Among the patients in the untreated sterile group 21 and 32% were stone-free at 6 and 12 months, respectively. In the infection group these figures were 27 and 40%, respectively. Among the untreated sterile calcium stone patients in whom clearance was not achieved, a high percentage experienced residual fragment growth or re-aggregation. The use of citrate therapy significantly improved the stone clearance rate in the sterile (at 6 and 12 months 65 and 74% were stone-free, respectively) and infection (71 and 86%, respectively) stone patients, and prevented residual fragment growth or re-aggregation in patients in whom clearance was not achieved. The data show that growth and persistence are common in the natural history of residual stone fragments. Citrate ameliorated the outcome of these residual fragments by reducing the growth or agglomeration, and by increasing the clearance rate in calcium oxalate and in infection-stone patients.
In a retrospective, non-randomized review by Fine et al. [15] , they evaluated 80 patients who were referred for metabolic evaluation and medical management of stone disease after ESWL. Of all the patients 31 were determined to be stone-free following lithotripsy, while 49 had residual stone fragments. Patients were placed into four groups after shock wave lithotripsy: stone-free or residual fragments on or off medical therapy. In the stone-free group (19 patients), medical treatment produced a significant decrease in stone formation from a median of 0.67 to 0.0 stones per patient per year (P < 0.001). In 36 patients with residual fragments stone formation before shock-wave lithotripsy was higher than in the stone-free group but there was also a significant decrease in the stone-formation rate from a median of 2.47 to 0.00 stones per patient per year while on medical therapy (P < 0.001). In 13 patients with residual fragments not on medical treatment there was only a minimal decrease in the stone-formation rate from a median of 1.33 to 0.77 stones per patient per year. The significance of so-called clinically insignificant residual fragments (smaller than 5 mm) following shock-wave lithotripsy in 26 out of 36 patients with residual fragments was also assessed. More than half of the 26 patients with CIRF in the group who did not continue on medical therapy demonstrated significant stone growth during follow up, suggesting that these fragments were not insignificant. Moreover, only 16% of the patients with fragments smaller than 5 mm demonstrated an increase in fragment size while on medical therapy, again suggesting that appropriate medical treatment can decrease the risk of recurrent stone formation or growth.
Soygur et al. [16] evaluated the efficacy of potassium citrate treatment in preventing stone recurrences and residual fragments after SWL for lower pole calcium oxalate urolithiasis. One hundred and ten patients who underwent ESWL because of lower-caliceal stones and who were stone-free or who had residual stone 4 weeks later were enrolled in the study. The average patient age was 41.7 years. All patients had documented simple calcium oxalate lithiasis without urinary tract infection and with normal renal morphology and function. Four weeks after ESWL, patients who were stone-free (n ¼ 56) and patients who had residual stones (n ¼ 34) were independently randomized into two subgroups that were matched for sex, age, and urinary values of citrate, calcium, and uric acid. One group was given oral potassium citrate 60 mEq per day, and the other group served as controls. In patients who were stone-free after ESWL and receiving medical treatment, the stone recurrence rate at 12 months was zero whereas untreated patients showed a 28.5% stone-recurrence rate (P < 0.05). Similarly, in the residual fragment group, the medically treated patients had a significantly greater remission rate than the untreated patients (44.5 versus 12.5%; P < 0.05). The conclusion was that potassium citrate therapy significantly alleviated calcium oxalate stone activity after ESWL for lower-pole stones in patients who were stone-free. An important observation was the beneficial effect of medical treatment on stone activity after ESWL among patients with residual calculi. Citrate treatment significantly improved the outcome of the residual fragments by decreasing growth. Such therapy might allow spontaneous passage and thus increasing the clearance rate.
In-vitro studies by Chow et al. [17 ] showed that citrate inhibited stone growth in the laboratory model. The higher citrate concentration significantly reduced the growth rate of stones by more than 50%. This adds to evidence justifying the use of alkaline citrate in calcium oxalate nephrolithiasis.
Conclusion
The term CIRF is a misnomer. The concept is controversial and needs to be redefined. It has no impact on the subsequent risks of stone growth, significant symptomatic events and need for secondary intervention. Residual fragments require close monitoring for stone growth, potential complications and subsequent intervention. While most small residual stone fragments might be managed expectantly, a significant number of patients might become symptomatic or require intervention. Therefore, the use of the term clinically insignificant for any small post-ESWL stone fragments might not be appropriate in the present context. Routine repeat ESWL treatment or endourological treatment of residual stones to achieve stone-free status is not necessary. Secondary procedures, however, can be applied selectively to those patients who have significant symptoms of obstruction associated with the residual stone. Medical therapy might play an important role in the management of residual fragments.
